Officer David C. Myles files intent to sell $1.38M in Olema Pharmaceuticals stock, continuing recent sales.
OLMA has more than doubled off its 52-week low of $2.86 on light trading volume (0.3× avg).
Summary
An officer at Olema Pharmaceuticals has filed to sell $1.38 million in stock, adding to over $1.8 million in sales by the same individual and an associated entity in the last three months.
Key Events · Ownership and Investor Activity · OLMA
-
Officer Files Intent to Sell
David C. Myles, an officer, filed a Form 144 to sell 50,000 shares of Olema Pharmaceuticals common stock.
-
Significant Proposed Value
The proposed sale is valued at approximately $1.38 million based on the current stock price.
-
Pattern of Recent Dispositions
This filing follows previous sales by Myles and an associated entity totaling over $1.8 million in the last three months.
-
Acquisition via Option Exercise
The securities to be sold were acquired through an option grant on February 1, 2023.
Analysis · OLMA · Life Sciences
David C. Myles, an officer at Olema Pharmaceuticals, has filed a Form 144 indicating an intent to sell 50,000 shares of common stock, valued at approximately $1.38 million. This proposed sale follows previous dispositions by Myles and an entity associated with him totaling over $1.8 million in the past three months. While the current proposed sale represents a small fraction of the company's market capitalization, the consistent pattern of selling by a key officer could be interpreted as a lack of conviction or a move to diversify holdings. Investors should monitor future insider activity.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.7% of the 1739 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OLMA was trading at $27.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $2.86 to $36.26. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.